Please wait a moment until all data is loaded. This message will disappear when all data is loaded.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Ala-Ala-Phe-7-amido-4-methylcoumarin + H2O
Ala-Ala-Phe + 7-amino-4-methylcoumarin
amyloid-beta + H2O
?
AbetaCy3 peptides are released from the nanofibrils due to TPP1 activity
-
-
?
amyloid-beta1-42 + H2O
?
the 34 Abeta end of the substrate shows integrated peak areas for peptide fragments 21-34, 22-34, and 23-34, indicative of cleavage after residue L34. The most abundant cleavages occur after residues Y10, G33, L34, and A30, and these cleavages occur more rapidly at pH 3.0 than at pH 4.5, consistent with endopeptidase activity. Peptides ending at residues E11, L17, F20, G37, and G38, are detected with lower abundances. At later times, the abundance of some of the peptides may decrease due to further proteolysis by TPP1. TPP1 can proteolyze monomeric Abeta1-42 efficiently at acidic pH
-
-
?
epsilon-aminocaproyl-WFFIQ-[N-(2,4-dinitrophenyl)-ethylenediamine] + H2O
epsilon-aminocaproyl-WF + FIQ-[N-(2,4-dinitrophenyl)-ethylenediamine]
-
-
-
?
KWFFIQ-[N-(2,4-dinitrophenyl)-ethylenediamine] + H2O
KWF + FIQ-[N-(2,4-dinitrophenyl)-ethylenediamine]
-
-
-
?
L-Ala-L-Ala-L-Phe-7-amido-4-methylcoumarin + H2O
L-Ala-L-Ala-L-Phe + 7-amino-4-methylcoumarin
L-Arg-L-Nle-L-Nle-7-amido-4-methylcoumarin + H2O
L-Arg-L-Nle-L-Nle + 7-amino-4-methylcoumarin
-
-
-
?
RWFFIQ-[N-(2,4-dinitrophenyl)-ethylenediamine] + H2O
RWF + FIQ-[N-(2,4-dinitrophenyl)-ethylenediamine]
FRET substrate
-
-
?
RWFVIQ-[N-(2,4-dinitrophenyl)-ethylenediamine] + H2O
RWF + VIQ-[N-(2,4-dinitrophenyl)-ethylenediamine]
-
-
-
?
Ala-Ala-Phe-7-amido-4-carbamoylmethylcoumarin + H2O
Ala-Ala-Phe + 7-amino-4-carbamoylmethylcoumarin
-
-
-
-
?
Ala-Ala-Phe-7-amido-4-methylcoumarin + H2O
Ala-Ala-Phe + 7-amino-4-methylcoumarin
-
-
-
-
?
Ala-Ala-Phe-p-nitrophenylalanyl-Arg-Leu + H2O
Ala-Ala-Phe + p-nitrophenylalanyl-Arg-Leu
-
-
-
-
?
Ala-Arg-Phe-p-nitrophenylalanyl-Arg-Leu + H2O
Ala-Arg-Phe + p-nitrophenylalanyl-Arg-Leu
-
-
-
-
?
Ala-Asp-Phe-p-nitrophenylalanyl-Arg-Leu + H2O
Ala-Asp-Phe + p-nitrophenylalanyl-Arg-Leu
-
-
-
-
?
Ala-His-Phe-p-nitrophenylalanyl-Arg-Leu + H2O
Ala-His-Phe + p-nitrophenylalanyl-Arg-Leu
-
-
-
-
?
Ala-Nle-Leu-7-amido-4-carbamoylmethylcoumarin + H2O
Ala-Nle-Leu + 7-amino-4-carbamoylmethylcoumarin
-
-
-
-
?
Ala-Nle-Nle-7-amido-4-carbamoylmethylcoumarin + H2O
Ala-Nle-Nle + 7-amino-4-carbamoylmethylcoumarin
-
-
-
-
?
Ala-Nva-Nle-7-amido-4-carbamoylmethylcoumarin + H2O
Ala-Nva-Nle + 7-amino-4-carbamoylmethylcoumarin
-
-
-
-
?
Ala-Ser-Phe-p-nitrophenylalanyl-Arg-Leu + H2O
Ala-Ser-Phe + p-nitrophenylalanyl-Arg-Leu
-
-
-
-
?
Arg-Ala-Phe-p-nitrophenylalanyl-Arg-Leu + H2O
Arg-Ala-Phe + p-nitrophenylalanyl-Arg-Leu
-
-
-
-
?
Arg-Pro-Phe-7-amido-4-carbamoylmethylcoumarin + H2O
Arg-Pro-Phe + 7-amino-4-carbamoylmethylcoumarin
-
-
-
-
?
Asp-Ala-Phe-p-nitrophenylalanyl-Arg-Leu + H2O
Asp-Ala-Phe + p-nitrophenylalanyl-Arg-Leu
-
-
-
-
?
Cholecystokinin + H2O
?
-
-
-
-
?
Gly-Pro-Met 2-naphthylamide + H2O
Gly-Pro-Met + 2-naphthylamine
-
-
-
?
His-Ala-Phe-p-nitrophenylalanyl-Arg-Leu + H2O
His-Ala-Phe + p-nitrophenylalanyl-Arg-Leu
-
-
-
-
?
L-Ala-L-Ala-L-Phe-7-amido-4-methylcoumarin + H2O
L-Ala-L-Ala-L-Phe + 7-amino-4-methylcoumarin
-
-
-
-
?
Neuromedin B + H2O
?
-
-
-
-
?
Ser-Ala-Phe-p-nitrophenylalanyl-Arg-Leu + H2O
Ser-Ala-Phe + p-nitrophenylalanyl-Arg-Leu
-
-
-
-
?
subunit C of mitochondrial ATP synthase + H2O
?
-
-
-
-
?
synthetic collagen-like polypetides + H2O
Gly-Pro-Xaa tripeptides
-
-
-
?
[Ala-Ala-Phe]2-rhodamine 110 + H2O
[Ala-Ala-Phe]2 + rhodamine 110
-
specific substrate for determining TPP-I activity and intracellular localization in living cells
-
-
?
[Arg-Nle-Nle]2-rhodamine 110 + H2O
[Ala-Ala-Phe]2 + rhodamine 110
-
specific substrate for determining TPP-I activity and intracellular localization in living cells
-
-
?
additional information
?
-
Ala-Ala-Phe-7-amido-4-methylcoumarin + H2O
Ala-Ala-Phe + 7-amino-4-methylcoumarin
-
-
-
?
Ala-Ala-Phe-7-amido-4-methylcoumarin + H2O
Ala-Ala-Phe + 7-amino-4-methylcoumarin
-
-
-
-
?
Ala-Ala-Phe-7-amido-4-methylcoumarin + H2O
Ala-Ala-Phe + 7-amino-4-methylcoumarin
-
-
-
?
L-Ala-L-Ala-L-Phe-7-amido-4-methylcoumarin + H2O
L-Ala-L-Ala-L-Phe + 7-amino-4-methylcoumarin
-
-
-
?
L-Ala-L-Ala-L-Phe-7-amido-4-methylcoumarin + H2O
L-Ala-L-Ala-L-Phe + 7-amino-4-methylcoumarin
-
-
-
-
?
additional information
?
-
validation and evaluation of a rapid and simple fluorometric tripeptidyl peptidase 1 (TPP1) assay using dried blood specimens to diagnose CLN2 disease
-
-
?
additional information
?
-
-
validation and evaluation of a rapid and simple fluorometric tripeptidyl peptidase 1 (TPP1) assay using dried blood specimens to diagnose CLN2 disease
-
-
?
additional information
?
-
-
succinyl-Ala-Ala-Phe-7-amido-4-methylcoumarin, succinyl-Gly-Pro-Leu 4-methylcoumarin 7-amide, Gly-Pro-7-amido-4-methylcoumarin, Gly-7-amido-4-methylcoumarin, Pro-7-amido-4-methylcoumarin, Met-7-amido-4-methylcoumarin, Ala 7-amido-4-methylcoumarin, Phe-7-amido-4-methylcoumarin, or Leu-7-amido-4-methylcoumarin
-
-
?
additional information
?
-
-
the enzyme removes tripeptides from the free N-termini of small polypeptides and also shows a minor endoprotease activity
-
-
?
additional information
?
-
-
absolute requirement for unsubstituted amino-terminus
-
-
?
additional information
?
-
-
involved in degradation of bone collagen
-
-
?
additional information
?
-
-
classical late infantile neuronal ceroid lipofuscinosis is an autosomal recessive disease caused by mutations in the CLN2 gene resulting in functional defects of the gene product tripeptidyl-peptidase I. This disease is associated with a progressive neurodegenerative course beginning at the age of two years with developmental stagnation, finally leading to a complete loss of motor function, vision and speech by the age of 10 years
-
-
?
additional information
?
-
-
elevated enzyme activity of tripeptidyl peptidase I and other lysosomal enzymes in Sjoegren's syndrome patients may play a role in tissue damage by accelerated breakdown of glycoproteins in lysosomes
-
-
?
additional information
?
-
-
TPP I is the predominant proteolytic enzyme responsible for the intracellular degradation of neuromedin B. The inability of cells from patients with late-infantile neuronal ceroid lipofuscinosis (CNL2) to degrade neuromedin B and other neuropeptides may contribute to the pathogenesis of the disease
-
-
?
additional information
?
-
-
determination of the substrate specificity of tripeptidyl-peptidase I using combinatorial peptide libraries and development of improved fluorogenic substrates
-
-
?
additional information
?
-
-
prefers Leu, Phe and Nle at the P1 position, whereas Asn, His, Lys, Arg, Ser, Val, Ile, Thr, Gly and Pro are highly unfavored in this position, showing less than 1% of the activity of the best substrates
-
-
?
additional information
?
-
-
TPP I acts preferentially on small, unstructured oligopeptides of less than 5 kDa
-
-
?
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Amyotrophic Lateral Sclerosis
Trehalose induces autophagy via lysosomal-mediated TFEB activation in models of motoneuron degeneration.
Arthritis, Rheumatoid
Lysosomal peptidases and glycosidases in rheumatoid arthritis.
Ataxia
Autosomal Recessive Spinocerebellar Ataxia 7 (SCAR7) is Caused by Variants in TPP1, The Gene Involved in Classic Late-Infantile Neuronal Ceroid Lipofuscinosis 2 Disease (CLN2 Disease).
Blindness
Management Strategies for CLN2 Disease.
Bone Resorption
Inhibition of bone resorption by inhibitors of tripeptidyl peptidase-I.
Bone Resorption
Purification and characterization of a tripeptidyl peptidase I from human osteoclastomas: evidence for its role in bone resorption.
Brain Injuries
[A primary study on the ARP-SRP gene expression profiling of brain injury by cDNA microarray]
Breast Neoplasms
A lysosomal pepstatin-insensitive proteinase as a novel biomarker for breast carcinoma.
Bulbo-Spinal Atrophy, X-Linked
Trehalose induces autophagy via lysosomal-mediated TFEB activation in models of motoneuron degeneration.
Carcinoma
Significance and prognostic value of lysosomal enzyme activities measured in surgically operated adenocarcinomas of the gastroesophageal junction and squamous cell carcinomas of the lower third of esophagus.
Carcinoma, Squamous Cell
Significance and prognostic value of lysosomal enzyme activities measured in surgically operated adenocarcinomas of the gastroesophageal junction and squamous cell carcinomas of the lower third of esophagus.
Cysts
The lysosomal aminopeptidase tripeptidyl peptidase 1 displays increased activity in malignant pancreatic cysts.
Dementia
Study of Intraventricular Cerliponase Alfa for CLN2 Disease.
Dementia
Validity of a rapid and simple fluorometric tripeptidyl peptidase 1 (TPP1) assay using dried blood specimens to diagnose CLN2 disease.
Epilepsy
Autosomal Recessive Spinocerebellar Ataxia 7 (SCAR7) is Caused by Variants in TPP1, The Gene Involved in Classic Late-Infantile Neuronal Ceroid Lipofuscinosis 2 Disease (CLN2 Disease).
Epilepsy
Disease characteristics and progression in patients with late-infantile neuronal ceroid lipofuscinosis type 2 (CLN2) disease: an observational cohort study.
Epilepsy
Validity of a rapid and simple fluorometric tripeptidyl peptidase 1 (TPP1) assay using dried blood specimens to diagnose CLN2 disease.
Gangliosidoses, GM2
Tripeptidyl-peptidase I in neuronal ceroid lipofuscinoses and other lysosomal storage disorders.
Genetic Diseases, Inborn
Clinical protocol. Administration of a replication-deficient adeno-associated virus gene transfer vector expressing the human CLN2 cDNA to the brain of children with late infantile neuronal ceroid lipofuscinosis.
Genetic Diseases, Inborn
Systemic administration of tripeptidyl peptidase I in a mouse model of late infantile neuronal ceroid lipofuscinosis: effect of glycan modification.
Genetic Diseases, Inborn
Validity of a rapid and simple fluorometric tripeptidyl peptidase 1 (TPP1) assay using dried blood specimens to diagnose CLN2 disease.
Heredodegenerative Disorders, Nervous System
Residual levels of tripeptidyl-peptidase I activity dramatically ameliorate disease in late-infantile neuronal ceroid lipofuscinosis.
Heredodegenerative Disorders, Nervous System
The human CLN2 protein/tripeptidyl-peptidase I is a serine protease that autoactivates at acidic pH.
Huntington Disease
Trehalose induces autophagy via lysosomal-mediated TFEB activation in models of motoneuron degeneration.
Lafora Disease
Advances in the genetics of progressive myoclonus epilepsy.
Language Development Disorders
Management Strategies for CLN2 Disease.
Lysosomal Storage Diseases
Assessment of Disease Severity in Late Infantile Neuronal Ceroid Lipofuscinosis Using Multiparametric MR Imaging.
Lysosomal Storage Diseases
Central nervous system stem cell transplantation for children with neuronal ceroid lipofuscinosis.
Lysosomal Storage Diseases
Classical late infantile neuronal ceroid lipofuscinosis fibroblasts are deficient in lysosomal tripeptidyl peptidase I.
Lysosomal Storage Diseases
Guidelines on the diagnosis, clinical assessments, treatment and management for CLN2 disease patients.
Lysosomal Storage Diseases
Slowing late infantile Batten disease by direct brain parenchymal administration of a rh.10 adeno-associated virus expressing CLN2.
Lysosomal Storage Diseases
The lysosomal degradation of neuromedin B is dependent on tripeptidyl peptidase-I: evidence for the impairment of neuropeptide degradation in late-infantile neuronal ceroid lipofuscinosis.
Lysosomal Storage Diseases
The specificity of lysosomal tripeptidyl peptidase-I determined by its action on angiotensin-II analogues.
Lysosomal Storage Diseases
Tripeptidyl peptidases: enzymes that count.
Melanoma
Impact of Gln94Glu mutation on the structure and function of protection of telomere 1, a cause of cutaneous familial melanoma.
MERRF Syndrome
Advances in the genetics of progressive myoclonus epilepsy.
Muscular Atrophy
Trehalose induces autophagy via lysosomal-mediated TFEB activation in models of motoneuron degeneration.
Neoplasms
A lysosomal pepstatin-insensitive proteinase as a novel biomarker for breast carcinoma.
Neoplasms
Purification and characterization of a tripeptidyl peptidase I from human osteoclastomas: evidence for its role in bone resorption.
Nervous System Diseases
Crystal structure and autoactivation pathway of the precursor form of human tripeptidyl-peptidase 1, the enzyme deficient in late infantile ceroid lipofuscinosis.
Neuroblastoma
Trehalose induces autophagy via lysosomal-mediated TFEB activation in models of motoneuron degeneration.
Neurodegenerative Diseases
A mouse model of classical late-infantile neuronal ceroid lipofuscinosis based on targeted disruption of the CLN2 gene results in a loss of tripeptidyl-peptidase I activity and progressive neurodegeneration.
Neurodegenerative Diseases
A tripeptidyl peptidase 1 is a binding partner of the Golgi pH regulator (GPHR) in Dictyostelium.
Neurodegenerative Diseases
A zebrafish model of CLN2 disease is deficient in tripeptidyl peptidase 1 and displays progressive neurodegeneration accompanied by a reduction in proliferation.
Neurodegenerative Diseases
AAV gene transfer delays disease onset in a TPP1-deficient canine model of the late infantile form of Batten disease.
Neurodegenerative Diseases
Analysis of catalytic properties of tripeptidyl peptidase I (TTP-I), a serine carboxyl lysosomal protease, and its detection in tissue extracts using selective FRET peptide substrate.
Neurodegenerative Diseases
Catalytic residues and substrate specificity of recombinant human tripeptidyl peptidase I (CLN2).
Neurodegenerative Diseases
Chronic Enzyme Replacement to the Brain of a Late Infantile Neuronal Ceroid Lipofuscinosis Mouse Has Differential Effects on Phenotypes of Disease.
Neurodegenerative Diseases
Clinical Pharmacokinetics and Pharmacodynamics of Cerliponase Alfa, Enzyme Replacement Therapy for CLN2 Disease by Intracerebroventricular Administration.
Neurodegenerative Diseases
Detection of tripeptidyl peptidase I activity in living cells by fluorogenic substrates.
Neurodegenerative Diseases
Determination of the substrate specificity of tripeptidyl-peptidase I using combinatorial peptide libraries and development of improved fluorogenic substrates.
Neurodegenerative Diseases
Diagnosis of neuronal ceroid lipofuscinosis type 2 (CLN2 disease): Expert recommendations for early detection and laboratory diagnosis.
Neurodegenerative Diseases
Dipeptidyl-peptidase I does not functionally compensate for the loss of tripeptidyl-peptidase I in the neurodegenerative disease late-infantile neuronal ceroid lipofuscinosis.
Neurodegenerative Diseases
First-trimester diagnosis of late-infantile neuronal ceroid lipofuscinosis (LINCL) by tripeptidyl peptidase I assay and CLN2 mutation analysis.
Neurodegenerative Diseases
Gemfibrozil, food and drug administration-approved lipid-lowering drug, increases longevity in mouse model of late infantile neuronal ceroid lipofuscinosis.
Neurodegenerative Diseases
Genetic modulation of apoptotic pathways fails to alter disease course in tripeptidyl-peptidase 1 deficient mice.
Neurodegenerative Diseases
Glial fibrillary acidic protein is elevated in the lysosomal storage disease classical late-infantile neuronal ceroid lipofuscinosis but is not a component of the storage material.
Neurodegenerative Diseases
Inducible transgenic expression of tripeptidyl peptidase 1 in a mouse model of late-infantile neuronal ceroid lipofuscinosis.
Neurodegenerative Diseases
Intraventricular Enzyme Replacement Improves Disease Phenotypes in a Mouse Model of Late Infantile Neuronal Ceroid Lipofuscinosis.
Neurodegenerative Diseases
Intraventricular enzyme replacement improves disease phenotypes in a mouse model of late infantile neuronal ceroid lipofuscinosis.
Neurodegenerative Diseases
Lysosomal degradation of cholecystokinin-(29-33)-amide in mouse brain is dependent on tripeptidyl peptidase-I: implications for the degradation and storage of peptides in classical late-infantile neuronal ceroid lipofuscinosis.
Neurodegenerative Diseases
Specific substrate for CLN2 protease/tripeptidyl-peptidase I assay.
Neurodegenerative Diseases
Structure of tripeptidyl-peptidase I provides insight into the molecular basis of late infantile neuronal ceroid lipofuscinosis.
Neurodegenerative Diseases
Trehalose induces autophagy via lysosomal-mediated TFEB activation in models of motoneuron degeneration.
Neurodegenerative Diseases
Tripeptidyl peptidase-I is essential for the degradation of sulphated cholecystokinin-8 (CCK-8S) by mouse brain lysosomes.
Neurodegenerative Diseases
Tripeptidyl-peptidase I in health and disease.
Neuronal Ceroid-Lipofuscinoses
A Basic ApoE-Based Peptide Mediator to Deliver Proteins across the Blood-Brain Barrier: Long-Term Efficacy, Toxicity, and Mechanism.
Neuronal Ceroid-Lipofuscinoses
A mouse model of classical late-infantile neuronal ceroid lipofuscinosis based on targeted disruption of the CLN2 gene results in a loss of tripeptidyl-peptidase I activity and progressive neurodegeneration.
Neuronal Ceroid-Lipofuscinoses
A tripeptidyl peptidase 1 is a binding partner of the Golgi pH regulator (GPHR) in Dictyostelium.
Neuronal Ceroid-Lipofuscinoses
AAV gene transfer delays disease onset in a TPP1-deficient canine model of the late infantile form of Batten disease.
Neuronal Ceroid-Lipofuscinoses
AAV2-mediated CLN2 gene transfer to rodent and non-human primate brain results in long-term TPP-I expression compatible with therapy for LINCL.
Neuronal Ceroid-Lipofuscinoses
Advances in the genetics of progressive myoclonus epilepsy.
Neuronal Ceroid-Lipofuscinoses
An Australasian diagnostic service for the neuronal ceroid lipofuscinoses.
Neuronal Ceroid-Lipofuscinoses
Aorsin, a novel serine proteinase with trypsin-like specificity at acidic pH.
Neuronal Ceroid-Lipofuscinoses
Autism, Epilepsy, and Neuroregression: Photosensitivity on Electroencephalography Solved the Riddle.
Neuronal Ceroid-Lipofuscinoses
Autosomal Recessive Spinocerebellar Ataxia 7 (SCAR7) is Caused by Variants in TPP1, The Gene Involved in Classic Late-Infantile Neuronal Ceroid Lipofuscinosis 2 Disease (CLN2 Disease).
Neuronal Ceroid-Lipofuscinoses
Central nervous system stem cell transplantation for children with neuronal ceroid lipofuscinosis.
Neuronal Ceroid-Lipofuscinoses
Chronic Enzyme Replacement to the Brain of a Late Infantile Neuronal Ceroid Lipofuscinosis Mouse Has Differential Effects on Phenotypes of Disease.
Neuronal Ceroid-Lipofuscinoses
Classical late infantile neuronal ceroid lipofuscinosis fibroblasts are deficient in lysosomal tripeptidyl peptidase I.
Neuronal Ceroid-Lipofuscinoses
Clinical study in Chinese patients with late-infantile form neuronal ceroid lipofuscinoses.
Neuronal Ceroid-Lipofuscinoses
Crystal structure and autoactivation pathway of the precursor form of human tripeptidyl-peptidase 1, the enzyme deficient in late infantile ceroid lipofuscinosis.
Neuronal Ceroid-Lipofuscinoses
Detection of tripeptidyl peptidase I activity in living cells by fluorogenic substrates.
Neuronal Ceroid-Lipofuscinoses
Determination of the substrate specificity of tripeptidyl-peptidase I using combinatorial peptide libraries and development of improved fluorogenic substrates.
Neuronal Ceroid-Lipofuscinoses
Developmental study of tripeptidyl peptidase I activity in the mouse central nervous system and peripheral organs.
Neuronal Ceroid-Lipofuscinoses
Diagnosis of late-infantile neuronal ceroid lipofuscinosis using dried blood spot-based assay for TPPI enzyme activity: TPPI diagnostic assay from DBS.
Neuronal Ceroid-Lipofuscinoses
Diagnosis of neuronal ceroid lipofuscinosis type 2 (CLN2 disease): Expert recommendations for early detection and laboratory diagnosis.
Neuronal Ceroid-Lipofuscinoses
Dipeptidyl-peptidase I does not functionally compensate for the loss of tripeptidyl-peptidase I in the neurodegenerative disease late-infantile neuronal ceroid lipofuscinosis.
Neuronal Ceroid-Lipofuscinoses
Disease characteristics and progression in patients with late-infantile neuronal ceroid lipofuscinosis type 2 (CLN2) disease: an observational cohort study.
Neuronal Ceroid-Lipofuscinoses
Distribution and development of CLN2 protein, the late-infantile neuronal ceroid lipofuscinosis gene product.
Neuronal Ceroid-Lipofuscinoses
Effective intravenous therapy for neurodegenerative disease with a therapeutic enzyme and a Peptide that mediates delivery to the brain.
Neuronal Ceroid-Lipofuscinoses
Enhanced Survival of the LINCL Mouse Following CLN2 Gene Transfer Using the rh.10 Rhesus Macaque-derived Adeno-associated Virus Vector.
Neuronal Ceroid-Lipofuscinoses
Enzyme replacement therapy with recombinant pro-CTSD (cathepsin D) corrects defective proteolysis and autophagy in neuronal ceroid lipofuscinosis.
Neuronal Ceroid-Lipofuscinoses
Enzyme-based diagnosis of classical late infantile neuronal ceroid lipofuscinosis: comparison of tripeptidyl peptidase I and pepstatin-insensitive protease assays.
Neuronal Ceroid-Lipofuscinoses
Exclusion of late infantile neuronal ceroid lipofuscinosis (LINCL) in a fetus by assay of tripeptidyl peptidase I in chorionic villi.
Neuronal Ceroid-Lipofuscinoses
First-trimester diagnosis of late-infantile neuronal ceroid lipofuscinosis (LINCL) by tripeptidyl peptidase I assay and CLN2 mutation analysis.
Neuronal Ceroid-Lipofuscinoses
Functional consequences and rescue potential of pathogenic missense mutations in tripeptidyl peptidase I.
Neuronal Ceroid-Lipofuscinoses
Gemfibrozil and fenofibrate, FDA-approved lipid-lowering drugs, upregulate tripeptidyl-peptidase 1 in brain cells via peroxisome proliferator-activated receptor-a: implications for late infantile neuronal ceroid lipofuscinosis therapy.
Neuronal Ceroid-Lipofuscinoses
Gemfibrozil, food and drug administration-approved lipid-lowering drug, increases longevity in mouse model of late infantile neuronal ceroid lipofuscinosis.
Neuronal Ceroid-Lipofuscinoses
Genetic modulation of apoptotic pathways fails to alter disease course in tripeptidyl-peptidase 1 deficient mice.
Neuronal Ceroid-Lipofuscinoses
Glial fibrillary acidic protein is elevated in the lysosomal storage disease classical late-infantile neuronal ceroid lipofuscinosis but is not a component of the storage material.
Neuronal Ceroid-Lipofuscinoses
Global Brain Transcriptome Analysis of a Tpp1 Neuronal Ceroid Lipofuscinoses Mouse Model.
Neuronal Ceroid-Lipofuscinoses
Inducible transgenic expression of tripeptidyl peptidase 1 in a mouse model of late-infantile neuronal ceroid lipofuscinosis.
Neuronal Ceroid-Lipofuscinoses
Intracerebroventricular Cerliponase Alfa for Neuronal Ceroid Lipofuscinosis Type 2 Disease: Clinical Practice Considerations From US Clinics.
Neuronal Ceroid-Lipofuscinoses
Intracranial delivery of CLN2 reduces brain pathology in a mouse model of classical late infantile neuronal ceroid lipofuscinosis.
Neuronal Ceroid-Lipofuscinoses
Intrathecal tripeptidyl-peptidase 1 reduces lysosomal storage in a canine model of late infantile neuronal ceroid lipofuscinosis.
Neuronal Ceroid-Lipofuscinoses
Intraventricular Enzyme Replacement Improves Disease Phenotypes in a Mouse Model of Late Infantile Neuronal Ceroid Lipofuscinosis.
Neuronal Ceroid-Lipofuscinoses
Intraventricular enzyme replacement improves disease phenotypes in a mouse model of late infantile neuronal ceroid lipofuscinosis.
Neuronal Ceroid-Lipofuscinoses
Late infantile neuronal ceroid lipofuscinosis: a new mutation in Arabs.
Neuronal Ceroid-Lipofuscinoses
Long Term Expression and Safety of Administration of AAVrh.10hCLN2 to the Brain of Rats and Non-human Primates for the Treatment of Late Infantile Neuronal Lipofuscinosis.
Neuronal Ceroid-Lipofuscinoses
Long-term expression and safety of administration of AAVrh.10hCLN2 to the brain of rats and nonhuman primates for the treatment of late infantile neuronal ceroid lipofuscinosis.
Neuronal Ceroid-Lipofuscinoses
Lysosomal degradation of cholecystokinin-(29-33)-amide in mouse brain is dependent on tripeptidyl peptidase-I: implications for the degradation and storage of peptides in classical late-infantile neuronal ceroid lipofuscinosis.
Neuronal Ceroid-Lipofuscinoses
Lysosomal protein thermal stability does not correlate with cellular half-life: global observations and a case study of tripeptidyl-peptidase 1.
Neuronal Ceroid-Lipofuscinoses
Mutation of the glycosylated asparagine residue 286 in human CLN2 protein results in loss of enzymatic activity.
Neuronal Ceroid-Lipofuscinoses
Mutation update: Review of TPP1 gene variants associated with neuronal ceroid lipofuscinosis CLN2 disease.
Neuronal Ceroid-Lipofuscinoses
Mutations in classical late infantile neuronal ceroid lipofuscinosis disrupt transport of tripeptidyl-peptidase I to lysosomes.
Neuronal Ceroid-Lipofuscinoses
Neurofilament light is a treatment-responsive biomarker in CLN2 disease.
Neuronal Ceroid-Lipofuscinoses
Neuronal ceroid lipofuscinosis type CLN2: a new rationale for the construction of phenotypic subgroups based on a survey of 25 cases in South America.
Neuronal Ceroid-Lipofuscinoses
Palmitoyl Protein Thioesterase1 (PPT1) and Tripeptidyl Peptidase-I (TPP-I) are expressed in the human saliva. A reliable and non-invasive source for the diagnosis of infantile (CLN1) and late infantile (CLN2) neuronal ceroid lipofuscinoses.
Neuronal Ceroid-Lipofuscinoses
Perampanel attenuates myoclonus in a patient with neuronal ceroid lipofuscinoses type 2 disease.
Neuronal Ceroid-Lipofuscinoses
Pre- and postnatal diagnosis of patients with CLN1 and CLN2 by assay of palmitoyl-protein thioesterase and tripeptidyl-peptidase I activities.
Neuronal Ceroid-Lipofuscinoses
Production and characterization of recombinant human CLN2 protein for enzyme-replacement therapy in late infantile neuronal ceroid lipofuscinosis.
Neuronal Ceroid-Lipofuscinoses
Residual levels of tripeptidyl-peptidase I activity dramatically ameliorate disease in late-infantile neuronal ceroid lipofuscinosis.
Neuronal Ceroid-Lipofuscinoses
Revealing the clinical phenotype of atypical neuronal ceroid lipofuscinosis type 2 disease: Insights from the largest cohort in the world.
Neuronal Ceroid-Lipofuscinoses
Safety of Direct Administration of AAV2(CU)hCLN2, a Candidate Treatment for the Central Nervous System Manifestations of Late Infantile Neuronal Ceroid Lipofuscinosis, to the Brain of Rats and Nonhuman Primates.
Neuronal Ceroid-Lipofuscinoses
Safety of direct administration of AAV2(CU)hCLN2, a candidate treatment for the central nervous system manifestations of late infantile neuronal ceroid lipofuscinosis, to the brain of rats and nonhuman primates.
Neuronal Ceroid-Lipofuscinoses
Slowing late infantile Batten disease by direct brain parenchymal administration of a rh.10 adeno-associated virus expressing CLN2.
Neuronal Ceroid-Lipofuscinoses
Specific substrate for CLN2 protease/tripeptidyl-peptidase I assay.
Neuronal Ceroid-Lipofuscinoses
Structure of tripeptidyl-peptidase I provides insight into the molecular basis of late infantile neuronal ceroid lipofuscinosis.
Neuronal Ceroid-Lipofuscinoses
Study of Intraventricular Cerliponase Alfa for CLN2 Disease.
Neuronal Ceroid-Lipofuscinoses
Survival advantage of neonatal CNS gene transfer for late infantile neuronal ceroid lipofuscinosis.
Neuronal Ceroid-Lipofuscinoses
Systemic administration of tripeptidyl peptidase I in a mouse model of late infantile neuronal ceroid lipofuscinosis: effect of glycan modification.
Neuronal Ceroid-Lipofuscinoses
The expression of tripeptidyl peptidase I in various tissues of rats and mice.
Neuronal Ceroid-Lipofuscinoses
The human CLN2 protein/tripeptidyl-peptidase I is a serine protease that autoactivates at acidic pH.
Neuronal Ceroid-Lipofuscinoses
The lysosomal degradation of neuromedin B is dependent on tripeptidyl peptidase-I: evidence for the impairment of neuropeptide degradation in late-infantile neuronal ceroid lipofuscinosis.
Neuronal Ceroid-Lipofuscinoses
The specificity of lysosomal tripeptidyl peptidase-I determined by its action on angiotensin-II analogues.
Neuronal Ceroid-Lipofuscinoses
The substrate range of tripeptidyl-peptidase I.
Neuronal Ceroid-Lipofuscinoses
Timing of therapeutic intervention determines functional and survival outcomes in a mouse model of late infantile batten disease.
Neuronal Ceroid-Lipofuscinoses
Tripeptidyl peptidase I, the late infantile neuronal ceroid lipofuscinosis gene product, initiates the lysosomal degradation of subunit c of ATP synthase.
Neuronal Ceroid-Lipofuscinoses
Tripeptidyl peptidase-I is essential for the degradation of sulphated cholecystokinin-8 (CCK-8S) by mouse brain lysosomes.
Neuronal Ceroid-Lipofuscinoses
Tripeptidyl peptidases: enzymes that count.
Neuronal Ceroid-Lipofuscinoses
Tripeptidyl-peptidase I deficiency in classical late-infantile neuronal ceroid lipofuscinosis brain tissue. Evidence for defective peptidase rather than proteinase activity.
Neuronal Ceroid-Lipofuscinoses
Tripeptidyl-peptidase I in health and disease.
Neuronal Ceroid-Lipofuscinoses
Tripeptidyl-peptidase I in neuronal ceroid lipofuscinoses and other lysosomal storage disorders.
Neuronal Ceroid-Lipofuscinoses
Tripeptidyl-peptidase I is apparently the CLN2 protein absent in classical late-infantile neuronal ceroid lipofuscinosis.
Neuronal Ceroid-Lipofuscinoses
Upregulation of tripeptidyl-peptidase 1 by 3-hydroxy-(2,2)-dimethyl butyrate, a brain endogenous ligand of PPAR?: Implications for late-infantile Batten disease therapy.
Neuronal Ceroid-Lipofuscinoses
Validity of a rapid and simple fluorometric tripeptidyl peptidase 1 (TPP1) assay using dried blood specimens to diagnose CLN2 disease.
Neuronal Ceroid-Lipofuscinoses
Viral-mediated delivery of the late-infantile neuronal ceroid lipofuscinosis gene, TPP-I to the mouse central nervous system.
Neuronal Ceroid-Lipofuscinoses
[Tripeptidyl peptidase 1 deficiency in neuronal ceroid lipofuscinosis. A novel mutation]
Pancreatic Cyst
The lysosomal aminopeptidase tripeptidyl peptidase 1 displays increased activity in malignant pancreatic cysts.
Parkinson Disease
Trehalose induces autophagy via lysosomal-mediated TFEB activation in models of motoneuron degeneration.
Seizures
Management Strategies for CLN2 Disease.
Seizures
Viral-mediated delivery of the late-infantile neuronal ceroid lipofuscinosis gene, TPP-I to the mouse central nervous system.
Spinocerebellar Ataxias
Trehalose induces autophagy via lysosomal-mediated TFEB activation in models of motoneuron degeneration.
tripeptidyl-peptidase i deficiency
Detection of tripeptidyl peptidase I activity in living cells by fluorogenic substrates.
tripeptidyl-peptidase i deficiency
First-trimester diagnosis of late-infantile neuronal ceroid lipofuscinosis (LINCL) by tripeptidyl peptidase I assay and CLN2 mutation analysis.
tripeptidyl-peptidase i deficiency
Intracerebroventricular Cerliponase Alfa for Neuronal Ceroid Lipofuscinosis Type 2 Disease: Clinical Practice Considerations From US Clinics.
tripeptidyl-peptidase i deficiency
Pre- and postnatal enzyme analysis for infantile, late infantile and adult neuronal ceroid lipofuscinosis (CLN1 and CLN2).
tripeptidyl-peptidase i deficiency
Tripeptidyl-peptidase I deficiency in classical late-infantile neuronal ceroid lipofuscinosis brain tissue. Evidence for defective peptidase rather than proteinase activity.
tripeptidyl-peptidase i deficiency
[Tripeptidyl peptidase 1 deficiency in neuronal ceroid lipofuscinosis. A novel mutation]
Unverricht-Lundborg Syndrome
Advances in the genetics of progressive myoclonus epilepsy.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
C365R
protein processing different from wild-type, mutant is not localized in lysosomes, intracellular trafficking of mutant is altered compared to wild-type, no enzymatic activity
D276A
kcat/Km is 21% of the wild-type value
D327A
kcat/Km is 6% of the wild-type value
D517A
lack of enzyme activity and processing
E272A
kcat/Km is 3% of the wild-type value
E343K
protein processing different from wild-type, mutant is not localized in lysosomes, intracellular trafficking of mutant is altered compared to wild-type, no enzymatic activity
G473R
the mutation probably compromises the active center and results in loss of proteolytic activity
G77R
protein processing different from wild-type, mutant is not localized in lysosomes, intracellular trafficking of mutant is altered compared to wild-type, 1% of wild-type activity
I287N
protein processing different from wild-type, mutant is not localized in lysosomes, intracellular trafficking of mutant is altered compared to wild-type, no enzymatic activity
K428N
no apparent conformational destabilization is observed for the missense mutation
P202L
protein processing different from wild-type, mutant is not localized in lysosomes, intracellular trafficking of mutant is altered compared to wild-type, no enzymatic activity
P544S
protein processing similar to wild-type, lysosomal localisation, 32.8% of wild-type activity
Q248P
the mutation probably compromises the active center and results in loss of proteolytic activity
Q442H
protein processing different from wild-type, mutant is not localized in lysosomes, intracellular trafficking of mutant is altered compared to wild-type, no enzymatic activity
R127Q
protein processing similar to wild-type,lysosomal localization, 43% of wild-type activity
R206C
protein processing different from wild-type, mutant is not localized in lysosomes, intracellular trafficking of mutant is altered compared to wild-type, 0.7% of wild-type activity
R266Q
no apparent conformational destabilization is observed for the missense mutation
R447H
protein processing different from wild-type, mutant is not localized in lysosomes, intracellular trafficking of mutant is altered compared to wild-type, 1.8% of wild-type activity
S475
inactive mutant enzyme
V216M
no apparent conformational destabilization is observed for the missense mutation
V227M
protein processing different from wild-type, mutant is not localized in lysosomes, intracellular trafficking of mutant is altered compared to wild-type, no enzymatic activity
V277M
the mutation probably compromises the active center and results in loss of proteolytic activity
C365R
-
decreased activity
D81A
-
not expressed in Sf9 cells
E343L
-
decreased activity
E77A
-
very low activity with Ala-Arg-Phe-p-nitrophenylalanyl-Arg-Leu
G284V
-
decreased activity
N286Q
-
the secreted proenzyme formes non-native, interchain disulfide bridges and displays only residual TPP I activity upon acidification. A small portion of the mutant enzyme reaches the lysosome and is processed to an active species, however, it shows low thermal and pH stability
P202L
-
decreased activity
R206C
-
decreased activity
R208X
-
mutation is identified in patients with late infantile ceroid lipofuscinosis, no detection of any translational product for the mutant
R447H
-
decreased activity
T353P
-
mutation is identified in patients with late infantile ceroid lipofuscinosis, enzyme shows 5.5% of wild-type enzyme when expressed in HEK cells, blocked processing to mature size peptidase leads to protein retention in the endoplasmic reticulum and rapid degradation in non-lysosomal compartments
V277M
-
decreased activity
D360A
lack of enzyme activity and processing
D360A
kcat/Km is 3% of the wild-type value
G284V
the mutation probably compromises the active center and results in loss of proteolytic activity
G284V
protein processing different from wild-type, mutant is not localized in lysosomes, intracellular trafficking of mutant is altered compared to wild-type, no enzymatic activity
N286S
the substitution results in loss of one glycosylation site, which leads to almost complete loss of protease activity
N286S
protein processing different from wild-type, mutant is not localized in lysosomes, intracellular trafficking of mutant is altered compared to wild-type, no enzymatic activity
S475L
kcat/Km is 0.4% of the wild-type value
S475L
the mutation probably compromises the active center and results in loss of proteolytic activity
S475L
protein processing similar to wild-type, lysosomal localization, no enzymatic activity
G77R
-
decreased activity
G77R
-
the mutation is associated with classic late infantile neuronal ceroid lipofuscinosis
I287N
-
decreased activity
I287N
-
mutation is identified in patients with late infantile ceroid lipofuscinosis, enzyme shows 4.1% of wild-type enzyme when expressed in HEK cells, blocked processing to mature size peptidase leads to protein retention in the endoplasmic reticulum and rapid degradation in non-lysosomal compartments
N286S
-
decreased activity
N286S
-
mutation is identified in patients with late infantile ceroid lipofuscinosis, enzyme shows 5.8% of wild-type enzyme when expressed in HEK cells, blocked processing to mature size peptidase leads to protein retention in the endoplasmic reticulum and rapid degradation in non-lysosomal compartments
P544S
-
decreased activity
P544S
-
demonstrates a normal polypeptide pattern on Western blots, enzyme activity, and lysosomal localization
Q422H
-
decreased activity
Q422H
-
mutation is identified in patients with late infantile ceroid lipofuscinosis, enzyme shows 4.7% of wild-type enzyme when expressed in HEK cells, blocked processing to mature size peptidase leads to protein retention in the endoplasmic reticulum and rapid degradation in non-lysosomal compartments
R127Q
-
decreased activity
R127Q
-
mutation is identified in patients with late infantile ceroid lipofuscinosis, enzyme shows 74.3% of wild-type enzyme when expressed in HEK cells
R127Q
-
demonstrates a normal polypeptide pattern on Western blots, enzyme activity, and lysosomal localization
S475L
-
inactive
S475L
-
decreased activity
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Page, A.E.; Fuller, K.; Chambers, T.J.; Warburton, M.J.
Purification and characterization of a tripeptidyl peptidase I from human osteoclastomas: evidence for its role in bone resorption
Arch. Biochem. Biophys.
306
354-359
1993
Homo sapiens
brenda
Golabek, A.A.; Kida, E.; Walus, M.; Wujek, P.; Mehta, P.; Wisniewski, K.E.
Biosynthesis, glycosylation, and enzymatic processing in vivo of human tripeptidyl-peptidase I
J. Biol. Chem.
278
7135-7145
2003
Homo sapiens
brenda
Lin, L.; Sohar, I.; Lackland, H.; Lobel, P.
The human CLN2 protein/tripeptidyl-peptidase I is a serine protease that autoactivates at acidic pH
J. Biol. Chem.
276
2249-2255
2001
Homo sapiens (O14773), Homo sapiens
brenda
Kopan, S.; Sivasubramaniam, U.; Warburton, M.J.
The lysosomal degradation of neuromedin B is dependent on tripeptidyl peptidase-I: evidence for the impairment of neuropeptide degradation in late-infantile neuronal ceroid lipofuscinosis
Biochem. Biophys. Res. Commun.
319
58-65
2004
Homo sapiens
brenda
Sohar, N.; Sohar, I.; Hammer, H.
Lysosomal enzyme activities: new potential markers for Sjoegrens syndrome
Clin. Biochem.
38
1120-1126
2005
Homo sapiens
brenda
Kohan, R.; Noher de Halac, I.; Anzolini, V.T.; Cismondi, A.; Oller Ramirez, A.M.; Capra, A.P.; Dodelson de Kremer, R.
Palmitoyl protein thioesterase 1 (PPT1) and tripeptidyl peptidase-I (TPP-I) are expressed in the human saliva. A reliable and non-invasive source for the diagnosis of infantile (CLN1) and late infantile (CLN2) neuronal ceroid lipofuscinoses
Clin. Biochem.
38
492-494
2005
Homo sapiens
brenda
Walus, M.; Kida, E.; Wisniewski, K.E.; Golabek, A.A.
Ser475, Glu272, Asp276, Asp327, and Asp360 are involved in catalytic activity of human tripeptidyl-peptidase I
FEBS Lett.
579
1383-1388
2005
Homo sapiens (O14773), Homo sapiens
brenda
Steinfeld, R.; Steinke, H.B.; Isbrandt, D.; Kohlschuetter, A.; Gaertner, J.
Mutations in classical late infantile neuronal ceroid lipofuscinosis disrupt transport of tripeptidyl-peptidase I to lysosomes
Hum. Mol. Genet.
13
2483-2491
2004
Homo sapiens
brenda
Oyama, H.; Fujisawa, T.; Suzuki, T.; Dunn, B.M.; Wlodawer, A.; Oda, K.
Catalytic residues and substrate specificity of recombinant human tripeptidyl peptidase I (CLN2)
J. Biochem.
138
127-134
2005
Homo sapiens
brenda
Wujek, P.; Kida, E.; Walus, M.; Wisniewski, K.E.; Golabek, A.A.
N-glycosylation is crucial for folding, trafficking, and stability of human tripeptidyl-peptidase I
J. Biol. Chem.
279
12827-12839
2004
Homo sapiens
brenda
Golabek, A.A.; Wujek, P.; Walus, M.; Bieler, S.; Soto, C.; Wisniewski, K.E.; Kida, E.
Maturation of human tripeptidyl-peptidase I in vitro
J. Biol. Chem.
279
31058-31067
2004
Homo sapiens
brenda
Golabek, A.A.; Walus, M.; Wisniewski, K.E.; Kida, E.
Glycosaminoglycans modulate activation, activity, and stability of tripeptidyl-peptidase I in vitro and in vivo
J. Biol. Chem.
280
7550-7561
2005
Homo sapiens
brenda
Tian, Y.; Sohar, I.; Taylor, J.W.; Lobel, P.
Determination of the substrate specificity of tripeptidyl-peptidase I using combinatorial peptide libraries and development of improved fluorogenic substrates
J. Biol. Chem.
281
6559-6572
2006
Homo sapiens
brenda
Steinfeld, R.; Fuhrmann, J.C.; Gaertner, J.
Detection of tripeptidyl peptidase I activity in living cells by fluorogenic substrates
J. Histochem. Cytochem.
54
991-996
2006
Homo sapiens
brenda
Kyttaelae, A.; Lahtinen, U.; Braulke, T.; Hofmann, S.L.
Functional biology of the neuronal ceroid lipofuscinoses (NCL) proteins
Biochim. Biophys. Acta
1762
920-933
2006
Homo sapiens
brenda
Golabek, A.A.; Kida, E.
Tripeptidyl-peptidase I in health and disease
Biol. Chem.
387
1091-1099
2006
Homo sapiens
brenda
Schroeder, B.; Elsaesser, H.P.; Schmidt, B.; Hasilik, A.
Characterisation of lipofuscin-like lysosomal inclusion bodies from human placenta
FEBS Lett.
581
102-108
2007
Homo sapiens (O14773), Homo sapiens
brenda
Leman, A.R.; Polochock, S.; Mole, S.E.; Pearce, D.A.; Rothberg, P.G.
Homogeneous PCR nucleobase quenching assays to detect four mutations that cause neuronal ceroid lipofuscinosis: T75P and R151X in CLN1, and IVS5-1G>C and R208X in CLN2
J. Neurosci. Methods
157
124-131
2006
Homo sapiens
brenda
Bessa, C.; Teixeira, C.A.; Dias, A.; Alves, M.; Rocha, S.; Lacerda, L.; Loureiro, L.; Guimaraes, A.; Ribeiro, M.G.
CLN2/TPP1 deficiency: the novel mutation IVS7-10A>G causes intron retention and is associated with a mild disease phenotype
Mol. Genet. Metab.
93
66-73
2008
Homo sapiens
brenda
Cabrera-Salazar, M.A.; Roskelley, E.M.; Bu, J.; Hodges, B.L.; Yew, N.; Dodge, J.C.; Shihabuddin, L.S.; Sohar, I.; Sleat, D.E.; Scheule, R.K.; Davidson, B.L.; Cheng, S.H.; Lobel, P.; Passini, M.A.
Timing of therapeutic intervention determines functional and survival outcomes in a mouse model of late infantile batten disease
Mol. Ther.
15
1782-1788
2007
Homo sapiens (O14773), Homo sapiens
brenda
Sondhi, D.; Hackett, N.R.; Peterson, D.A.; Stratton, J.; Baad, M.; Travis, K.M.; Wilson, J.M.; Crystal, R.G.
Enhanced survival of the LINCL mouse following CLN2 gene transfer using the rh.10 rhesus macaque-derived adeno-associated virus vector
Mol. Ther.
15
481-491
2007
Homo sapiens
brenda
Chang, M.; Cooper, J.D.; Sleat, D.E.; Cheng, S.H.; Dodge, J.C.; Passini, M.A.; Lobel, P.; Davidson, B.L.
Intraventricular enzyme replacement improves disease phenotypes in a mouse model of late infantile neuronal ceroid lipofuscinosis
Mol. Ther.
16
649-656
2008
Homo sapiens
brenda
Golabek, A.A.; Dolzhanskaya, N.; Walus, M.; Wisniewski, K.E.; Kida, E.
Prosegment of tripeptidyl peptidase I is a potent, slow-binding inhibitor of its cognate enzyme
J. Biol. Chem.
283
16497-16504
2008
Homo sapiens
brenda
Pal, A.; Kraetzner, R.; Gruene, T.; Grapp, M.; Schreiber, K.; Gronborg, M.; Urlaub, H.; Becker, S.; Asif, A.R.; Gaertner, J.; Sheldrick, G.M.; Steinfeld, R.
Structure of tripeptidyl-peptidase I provides insight into the molecular basis of late infantile neuronal ceroid lipofuscinosis
J. Biol. Chem.
284
3976-3984
2009
Homo sapiens (O14773)
brenda
Guhaniyogi, J.; Sohar, I.; Das, K.; Stock, A.M.; Lobel, P.
Crystal structure and autoactivation pathway of the precursor form of human tripeptidyl-peptidase 1, the enzyme deficient in late infantile ceroid lipofuscinosis
J. Biol. Chem.
284
3985-3997
2009
Homo sapiens (O14773), Homo sapiens
brenda
Walus, M.; Kida, E.; Golabek, A.A.
Functional consequences and rescue potential of pathogenic missense mutations in tripeptidyl peptidase I
Hum. Mutat.
31
710-721
2010
Homo sapiens (O14773), Homo sapiens
brenda
Lukacs, Z.; Nickel, M.; Murko, S.; Nieves Cobos, P.; Schulz, A.; Santer, R.; Kohlschuetter, A.
Validity of a rapid and simple fluorometric tripeptidyl peptidase 1 (TPP1) assay using dried blood specimens to diagnose CLN2 disease
Clin. Chim. Acta
492
69-71
2019
Homo sapiens (O14773), Homo sapiens
brenda
Kondo, M.Y.; Gouvea, I.E.; Okamoto, D.N.; Santos, J.A.; Souccar, C.; Oda, K.; Juliano, L.; Juliano, M.A.
Analysis of catalytic properties of tripeptidyl peptidase I (TTP-I), a serine carboxyl lysosomal protease, and its detection in tissue extracts using selective FRET peptide substrate
Peptides
76
80-86
2016
Homo sapiens (O14773), Rattus norvegicus (Q9EQV6), Rattus norvegicus Wistar (Q9EQV6)
brenda
Sole-Domenech, S.; Rojas, A.V.; Maisuradze, G.G.; Scheraga, H.A.; Lobel, P.; Maxfield, F.R.
Lysosomal enzyme tripeptidyl peptidase 1 destabilizes fibrillar Abeta by multiple endoproteolytic cleavages within the beta-sheet domain
Proc. Natl. Acad. Sci. USA
115
1493-1498
2018
Homo sapiens (O14773)
brenda